Acumen Pharmaceuticals (ABOS) Reiterated at Overweight by Cantor Fitzgerald

March 26, 2026 6:56 AM

Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS).The analyst commented, "We hosted the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found